Kane Biotech Inc.
KNBIF
$0.03
$0.006.40%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.78% | -103.75% | 17.99% | 33.48% | 51.90% |
| Total Depreciation and Amortization | -22.65% | -15.62% | -16.96% | 5.83% | -23.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.05% | 98.80% | -10.45% | -25.52% | -70.53% |
| Change in Net Operating Assets | -34.70% | 68.84% | -186.70% | -8.58% | -74.78% |
| Cash from Operations | -28.49% | 64.76% | -5.34% | 48.35% | 26.03% |
| Capital Expenditure | 100.00% | -- | -152.63% | 31.91% | -76.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.15% | 90.44% | -102.43% | -104.34% | 1,694.64% |
| Cash from Investing | 737.10% | -100.45% | -103.50% | -96.23% | 74.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 86.09% | 98.16% | 19.89% | -1.11% | -1.05% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -40.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 36.96% | 97.17% | 93.80% | -103.27% | 63.59% |
| Cash from Financing | -136.87% | 125.26% | 400.57% | -18.24% | -93.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.36% | 259.55% | 168.49% | -167.93% | -195.95% |